TransCode Therapeutics Earlier Issued Open Letter To Shareholders; Asks Shareholders To Give Co Authorization To Effect A Reverse Stock Split, As A Last Resort Incase The Nasdaq Panel Hearing Recommends Shares To Be Delisted
TransCode Therapeutics Earlier Issued Open Letter To Shareholders; Asks Shareholders To Give Co Authorization To Effect A Reverse Stock Split, As A Last Resort Incase The Nasdaq Panel Hearing Recommends Shares To Be Delisted
The Board and Management of TransCode Therapeutics (NASDAQ:RNAZ) today issued the following open letter to shareholders of the Company:
TransCode Therapeutics（纳斯达克股票代码：RNAZ）的董事会和管理层今天向公司股东发表了以下公开信：
The reason for requesting the authority to do the reverse split is that, as a last resort, we can inform the Panel that shareholders have authorized a reverse split. There is also no assurance that the authorization (alone or in combination with other reasons we will provide the Panel) will result in our stock not being delisted, but the company and its advisors believe this is our best chance.
请求授权进行反向拆分的原因是，作为最后的手段，我们可以告知小组，股东已经批准了反向拆分。也无法保证授权（单独或结合我们将向小组提供的其他理由）将导致我们的股票不被退市，但该公司及其顾问认为这是我们的最佳机会。
We believe having our stock continue to be listed on The Nasdaq Capital Market will be valuable in a number of ways in the future.
我们认为，让我们的股票继续在纳斯达克资本市场上市，将来在许多方面都具有价值。
We hope to not have to effect a reverse split, but we also believe that our shareholders are best served by doing everything we can to continue to be Nasdaq-listed.
我们希望不必进行反向拆分，但我们也认为，尽一切努力继续在纳斯达克上市，对我们的股东最有利。